Canada's Bausch Health Q3 revenue beats estimates on Salix, Solta demand

Bausch Health Companies

28/10/2026 20:14

Overview
Canada pharma firm's Q3 revenue rose 10% yr/yr, beating analyst expectations
Adjusted EPS for Q3 up 53% yr/yr
Company raised full-year 2026 revenue and adjusted EBITDA guidance

Outlook
Bausch Health raises 2026 revenue guidance to $10.975-$11.175 bln
Company now sees 2026 adjusted EBITDA at $4.315-$4.415 bln
Bausch Health expects 2026 adjusted cash flows from operations of $1.6-$1.675 bln
Company says tariff uncertainty may impact 2026 results

Result Drivers
SALIX SEGMENT - Growth driven by higher sales in Salix segment, led by Xifaxan, which saw 16% revenue growth
SOLTA MEDICAL ACQUISITION - Solta Medical segment growth aided by acquisition of distributor in China, offsetting organic decline in Asia Pacific
DERMATOLOGY - Diversified segment organic revenue increase primarily driven by double-digit growth in Dermatology

Company press release: ID:nCNWLftSba

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$2.94 bln
$2.76 bln (3 Analysts)
Q3 Net Income
 
$446 mln
 
Q3 Operating Income
 
$983 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
The stock recently traded at 1 times the next 12-month earnings vs. a P/E of 1 three months ago

Reuters Recommended Reads
Oct 28 - Bausch + Lomb beats Q3 adjusted EPS estimates; raises FY outlook
Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat
Oct 27 - Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)